Quotient Limited logo
Quotient Limited QTNT

Quarterly report 2022-Q4
added 02-09-2023

report update icon

Quotient Limited Financial Statements 2011-2026 | QTNT

Annual Financial Statements Quotient Limited

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

183 M 663 M 460 M 170 M 192 M 206 M 210 M 130 M - - -

Shares

91.6 M 71.6 M 54.9 M 40.8 M 28.1 M 19.6 M 14.8 M 18.4 M - - -

Historical Prices

2.59 5.21 9.51 6.12 4.95 4.84 16 18 - - -

Net Income

-111 M -103 M -105 M -82.3 M -85.1 M -33.9 M -59.1 M -10.2 M -4.71 M -4.47 M -4.62 M

Revenue

43.4 M 32.7 M 29.1 M 24.7 M 22.2 M 18.5 M 18.4 M 19.8 M 14.4 M 12.2 M 10 M

Cost of Revenue

20.1 M 17.8 M 17.2 M 10.5 M 10.8 M 9.66 M 9.76 M 8.41 M 7.17 M - -

Gross Profit

23.3 M 14.9 M 11.9 M 14.3 M 11.4 M 8.86 M 8.64 M 11.3 M 7.2 M 5.47 M 4.41 M

Operating Income

-82.7 M -80.4 M -79.2 M -70 M -74.1 M -49.1 M -29.7 M -8.89 M -4.49 M - -

Interest Expense

2.72 M 2.2 M -6.94 M 2.37 M -1.11 M 3.5 M -4.06 M -197 K 11 K - -

EBITDA

-73.9 M -68.4 M -66.2 M -59.6 M -64.6 M -46.1 M -28 M -8.27 M -3.8 M -2.98 M -3.12 M

Operating Expenses

106 M 95.5 M 90.9 M 84.2 M 85.4 M 58 M 38.4 M 20.2 M 11.7 M 9.43 M 8.5 M

General and Administrative Expenses

37.4 M 32 M 31.5 M 25.7 M 22.7 M 26.1 M 16.4 M 9.47 M 6.82 M 6.01 M 5.35 M

All numbers in USD currency

Quarterly Income Statement Quotient Limited

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

4.25 M 3.71 M 3.44 M 2.57 M 2.55 M 2.54 M 2.54 M 101 M 101 M 83.9 M 83.9 M 80.5 M 73.8 M 73.8 M 66.3 M 66.1 M 56.6 M 56.6 M 52.1 M 45.6 M 43.4 M 37.7 M 36.8 M 29.6 M 29.5 M 27.7 M 26.8 M 25.4 M 20.4 M 18.3 M 17.2 M 17 M 15.1 M 14.4 M 12.8 M 342 K 829 K 144 K 237 K - - - - - - - - -

Net Income

-13.3 M -98.1 M -84.8 M - -44.8 M -99.2 M -54.4 M -24.4 M -31.7 M -29.8 M -15 M -25.4 M -27.5 M -27.5 M -27 M -23.6 M -26.3 M -26.3 M -27.4 M - -20.3 M -21.7 M -20.2 M - -31.2 M -64.8 M -33.6 M - -9.78 M -24.4 M -14.6 M - -42.3 M -56.6 M -14.3 M - -3.27 M -4.95 M -1.68 M - - - - - - - - -

Revenue

9.95 M 27.6 M 17.7 M - 10.2 M 28.7 M 18.6 M 9.09 M 8.75 M 8.75 M 16.1 M 8.92 M 7.94 M 7.94 M 7.85 M 8.17 M 6.72 M 6.72 M 6.25 M - 5.86 M 5.91 M 6.83 M - 4.84 M 16.7 M 11.9 M - 4.35 M 13.5 M 9.12 M - 4.06 M 14.5 M 10.4 M - 3.91 M 15.1 M 11.2 M - - - - - - - - -

Cost of Revenue

3.9 M 31.1 M 27.2 M - 7.93 M 17.6 M 9.65 M 5.29 M 4.97 M 4.97 M 4.5 M 5.41 M 4.53 M 4.53 M 3.97 M 4.56 M 4.19 M 4.19 M 4.55 M - 2.32 M 2.79 M 2.83 M - 2.6 M 8.45 M 5.85 M - 2.22 M 7.1 M 4.88 M - 2.2 M 7.36 M 5.16 M - 1.94 M 6.27 M 4.33 M - - - - - - - - -

Gross Profit

6.05 M -3.52 M -9.57 M - 2.24 M 11.1 M 8.9 M 3.8 M 3.78 M 3.78 M 11.6 M 3.51 M 3.41 M 3.41 M 3.88 M 3.61 M 2.54 M 2.54 M 1.7 M - 3.53 M 3.12 M 3.99 M - 2.24 M 8.25 M 6.01 M - 2.13 M 6.38 M 4.25 M - 1.86 M 7.14 M 5.29 M - 1.97 M 8.83 M 6.86 M - - - - - - - - -

Operating Income

-25.6 M -89.1 M -63.5 M - -31.3 M -77 M -45.7 M -22 M -21.6 M -21.7 M -13.1 M -19.7 M -22.4 M -22.4 M -18.4 M -18.4 M -19 M -19 M -21.1 M - -17.1 M -18.1 M -16.9 M - -22.4 M -56.3 M -33.9 M - -12.8 M -36.2 M -23.5 M - -7.33 M -20 M -12.6 M - -2.8 M -4.29 M -1.49 M - - - - - - - - -

Interest Expense

20.6 M 1.01 M -19.6 M - -3.51 M 677 K 4.18 M 9.5 M 617 K 192 K 5 M 233 K 1.89 M 1.89 M -1.24 M 952 K -1.54 M -1.54 M -468 K - 33 K 565 K 880 K - -4.57 M -1.89 M 2.68 M - 305 K -987 K -1.29 M - 130 K -1.49 M 534 K - -45 K -83 K 77 K - - - - - - - - -

EBITDA

-25.6 M -89.1 M -63.5 M - -31.3 M -77 M -45.7 M -22 M -19.2 M -15.3 M -9.01 M -19.7 M -19.5 M -13.4 M -12.4 M -15.4 M -16 M -9.52 M -14.6 M - -14.5 M -15.5 M -14.4 M - -20.1 M -49.3 M -29.2 M - -12.1 M -34.7 M -22.6 M - -7.01 M -19 M -12.3 M - -2.8 M -3.91 M -1.25 M - - - - - - - - -

Operating Expenses

31.6 M 85.6 M 54 M - 33.5 M 88.1 M 54.6 M 25.8 M 25.4 M 25.5 M 24.7 M 23.2 M 25.8 M 25.8 M 22.3 M 22 M 21.6 M 21.6 M 22.8 M - 20.6 M 21.2 M 20.9 M - 24.7 M 64.6 M 39.9 M - 14.9 M 42.6 M 27.7 M - 9.18 M 27.1 M 17.9 M - 4.77 M 13.1 M 8.35 M - - - - - - - - -

General and Administrative Expenses

11.5 M 28.5 M 17.1 M - 15 M 32 M 17 M 8.98 M 7.52 M 7.52 M 8.23 M 8.58 M 8.12 M 8.12 M 5.98 M 6.62 M 6.47 M 6.47 M 6.76 M - 5.8 M 4.79 M 5.26 M - 4.54 M 13.6 M 9.09 M - 6.49 M 16.8 M 10.3 M - 3.64 M 10.6 M 6.98 M - 1.96 M 5.44 M 3.49 M - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Quotient Limited QTNT
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Quotient Limited plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Biodesix Biodesix
BDSX
$ 14.1 -3.46 % $ 1.83 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Sotera Health Company Sotera Health Company
SHC
$ 13.29 -1.88 % $ 3.77 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
$ 29.99 -5.78 % $ 1.52 B usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Neuronetics Neuronetics
STIM
$ 1.44 8.27 % $ 95 M usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 478.51 -2.12 % $ 180 B usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 0.6 -2.2 % $ 61.9 M irlandaIrlanda
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 45.31 -3.08 % $ 2.71 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 4.4 101.83 % $ 129 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Waters Corporation Waters Corporation
WAT
$ 292.64 -2.64 % $ 17.4 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 17.16 -1.15 % $ 384 M usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 158.44 -4.05 % $ 7.85 B usaUSA
Exagen Exagen
XGN
$ 2.67 -4.3 % $ 57.6 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 4.65 1.31 % $ 2.5 M usaUSA
Personalis Personalis
PSNL
$ 6.68 -8.76 % $ 396 M usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.73 2.37 % $ 7.59 M usaUSA
RadNet RadNet
RDNT
$ 57.44 -3.32 % $ 4.32 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Celcuity Celcuity
CELC
$ 110.97 -3.34 % $ 5.19 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 6.54 -0.38 % $ 273 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 268.45 0.03 % $ 22.3 B usaUSA
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.2 3.52 % $ 19.2 M singaporeSingapore
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Precipio Precipio
PRPO
$ 26.48 -2.65 % $ 34.4 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 17.08 -2.23 % $ 910 M usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain